Michele Laurel

Michele Laurel has a diverse work experience in the field of clinical quality assurance and regulatory compliance. Michele has held various leadership roles in different companies. Michele started their career in 2006 as a Project Manager at Kosan Biosciences, where they managed Phase II and II/III clinical research studies and led cross-functional teams. Michele then worked as a Sr. Clinical Project Manager at Cytokinetics and as a Sr. GCP Auditor at Clinical Auditing Network. In 2009, they joined Janssen, Pharmaceutical Companies of Johnson and Johnson, as a Senior Clinical Trial Manager. Michele later returned to Clinical Auditing Network as a Senior Auditing Specialist and then moved on to Theravance Biopharma US, Inc., where they served as a Sr. Manager of GCP Compliance. In 2017, they joined Sangamo Therapeutics, Inc. as the Director of Clinical Quality Assurance, where they established and led the Clinical QA and GCP Regulatory Compliance functions. Michele then worked as a CQA Project Lead at Vertex Pharmaceuticals in 2021, before joining Cortexyme, Inc. as the Executive Director of Clinical QA, where they were responsible for building infrastructure around ICH/GCP Inspection Readiness. In 2022, they joined Jasper Therapeutics as the Executive Director of Clinical QA.

Michele Laurel holds a Bachelor's degree in Zoology/Animal Biology from The University of Texas at Austin, which they earned between the years 1982 and 1986. Michele also holds a Master's degree in Biochemistry and Molecular Biology from The University of Texas at Austin. Michele's education also includes pursuing a Doctor of Philosophy (Ph.D.) degree in Molecular Biology, however, the status of completion is not provided.